New drug KUP-101A enters first human tests for advanced skin cancers
Disease control
Recruiting now
This early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measu…
Phase: PHASE1 • Sponsor: Kupando GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC